全文获取类型
收费全文 | 441篇 |
免费 | 32篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 8篇 |
妇产科学 | 12篇 |
基础医学 | 87篇 |
口腔科学 | 1篇 |
临床医学 | 64篇 |
内科学 | 151篇 |
神经病学 | 35篇 |
特种医学 | 7篇 |
外科学 | 48篇 |
综合类 | 17篇 |
预防医学 | 6篇 |
眼科学 | 3篇 |
药学 | 16篇 |
肿瘤学 | 26篇 |
出版年
2021年 | 9篇 |
2019年 | 10篇 |
2018年 | 11篇 |
2017年 | 8篇 |
2016年 | 4篇 |
2015年 | 6篇 |
2014年 | 11篇 |
2013年 | 14篇 |
2012年 | 17篇 |
2011年 | 13篇 |
2010年 | 16篇 |
2009年 | 14篇 |
2008年 | 12篇 |
2007年 | 26篇 |
2006年 | 24篇 |
2005年 | 26篇 |
2004年 | 16篇 |
2003年 | 15篇 |
2002年 | 12篇 |
2001年 | 22篇 |
2000年 | 10篇 |
1999年 | 6篇 |
1998年 | 7篇 |
1997年 | 13篇 |
1996年 | 6篇 |
1995年 | 5篇 |
1994年 | 7篇 |
1992年 | 16篇 |
1991年 | 10篇 |
1990年 | 15篇 |
1989年 | 8篇 |
1988年 | 9篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 11篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1982年 | 6篇 |
1981年 | 10篇 |
1980年 | 3篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1974年 | 2篇 |
1973年 | 4篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1968年 | 1篇 |
1962年 | 1篇 |
排序方式: 共有486条查询结果,搜索用时 875 毫秒
21.
A 43 year old man with a Hancock porcine bioprosthetic valve in the mitral position developed a huge thrombus filling the entire left atrium and chronic degeneration of the bioprosthetic mitral valve. The effective valve orifice was less than 2 mm. These severe findings leading to the patient's death remained undetected while he was alive. This case illustrates the great need for a serial phonoechocardiographic studies in all patients with prosthetic valves. 相似文献
22.
23.
24.
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. 总被引:6,自引:8,他引:6
S Charache G J Dover R D Moore S Eckert S K Ballas M Koshy P F Milner E P Orringer G Phillips O S Platt 《Blood》1992,79(10):2555-2565
Patients with sickle cell anemia were treated with daily doses of hydroxyurea, to assess pharmacokinetics, toxicity, and increase in fetal hemoglobin (Hb) production in response to the drug. Plasma hydroxyurea clearances were not a useful guide to maximum tolerated doses of the drug. The mean daily single oral dose that could be maintained for at least 16 weeks was 21 mg/kg (range, 10 to 35 mg/kg). Among 32 patients, last HbF levels were 1.9% to 26.3% (mean, 14.9%) with increases in HbF over initial values of 1.4% to 20.2% (mean, 11.2%). The most significant predictors of last HbF were last plasma hydroxyurea level, initial white blood count and initial HbF concentration. Last HbF was not related to beta globin haplotype or alpha globin gene number. No serious toxicity was encountered. Clinically significant bone marrow depression was avoided, and chromosome abnormalities after 2 years of treatment were no greater than those observed before treatment. The period of observation has been too short to evaluate the risk of carcinogenesis. Patient's red cells developed striking macrocytosis. Median red cell Hb concentrations did not change. Hb concentrations increased, on average 1.2 g/dL, but serum erythropoietin levels increased. Patients' body weights increased, and some returned to work or school, but no conclusions regarding therapeutic efficacy could be drawn from this uncontrolled open-label study. 相似文献
25.
The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) demonstrated the efficacy of hydroxyurea in reducing the rate of painful crises compared to placebo. We used resource utilization data collected in the MSH to determine the cost-effectiveness of hydroxyurea. The MSH was a randomized, placebo-controlled double-blind clinical trial involving 299 patients at 21 sites. The primary outcome, visit to a medical facility, was one of the criteria to define occurrence of painful crisis. Cost estimates were applied to all outpatient and emergency department visits and inpatient hospital stays that were classified as a crisis. Other resources for which cost estimates were applied included hospitalization for chest syndrome, analgesics received, hydroxyurea dosing, laboratory testing, and clinic visits for management of patient care. Annualized differential costs were calculated between hydroxyurea- and placebo-receiving patients. Hospitalization for painful crisis accounted for the majority of costs in both arms of the study, with an annual mean of $12,160 (95% CI: $9,440, $14,880) for hydroxyurea and $17,290 (95% CI: $13,010, $21,570) for placebo. The difference in means was $5,130 (95% CI: $60, $10,200; P = 0.048). Chest syndrome was the next largest cost with a mean difference of $830 (95% CI: $-340, $2,000; P = 0.16). The hydroxyurea arm was also associated with lower costs for emergency department visits, transfusion, and use of opiate analgesics. In total, the annual average cost per patient receiving hydroxyurea was $16,810 (95% CI: $13,350, $20,270) and the annual average costs per patient receiving placebo was $22,020 (95% CI: $17,340, $26,710). The difference in means was $5,210 (95% CI: $-610, $11,030; P = 0.21). The cost of hydroxyurea with the more intensive monitoring required when using this drug appears to be more than offset by decreased costs for medical care of painful crisis and analgesic use. Although the total cost difference was not significant statistically, these results suggest that hydroxyurea therapy is cost-effective compared to placebo in the management of adult patients with sickle cell anemia. If hydroxyurea can prevent development of chronic organ damage, long-term savings may be even greater. 相似文献
26.
Deepika S. Darbari Vivien A. Sheehan Samir K. Ballas 《European journal of haematology》2020,105(3):237-246
Early diagnosis, treatment, and prevention of a vaso-occlusive crisis (VOC) are critical to the management of patients with sickle cell disease. It is essential to differentiate between VOC-associated pain and chronic pain, hyperalgesia, neuropathy, and neuropathic pain. The pathophysiology of VOCs includes polymerization of abnormal sickle hemoglobin, inflammation, and adhesion. Hydroxyurea, L-glutamine, crizanlizumab, and voxelotor have been approved by the US Food and Drug Administration for reducing the frequency of VOCs; the European Medicines Agency has approved only hydroxyurea. Other novel treatments are in late-stage clinical development in both the United States and the European Union. The development of agents for prevention and treatment of VOCs should be driven by our understanding of its pathophysiology. 相似文献
27.
Sequential nitric oxide measurements during the emergency department treatment of acute vasoocclusive sickle cell crisis 总被引:1,自引:0,他引:1
This prospective study was designed to examine the relationship between serial serum nitric oxide (NO) levels and pain during the emergency department (ED) treatment of acute vasoocclusive sickle cell crisis (SCC). 102 patient visits, age > or =18 years of age, presenting to the ED with uncomplicated, typical SCC pain had serum NO levels obtained at 2-hr intervals during treatment of pain and were measured using an NO-specific chemiluminesence technique. Pain was measured prior to each NO measurement using a 10 cm visual analog scale (VAS), and subjects were divided into a persistent pain group and an improved pain group. Patients with persistent pain had significantly low initial NO levels (11.51 microM +/- 2.8, P < 0.05) while those with pain improvement had higher initial NO levels (18.1 microM +/- 3.08, P < 0.05). There was no significant correlation between changes in NO and changes in pain scores. These results suggest that the initial NO level may serve as a marker for the severity of tissue ischemia. Sequential NO levels do not appear useful in predicting the course of SCC. 相似文献
28.
Lampe JW Biggers CK Defauw JM Foglesong RJ Hall SE Heerding JM Hollinshead SP Hu H Hughes PF Jagdmann GE Johnson MG Lai YS Lowden CT Lynch MP Mendoza JS Murphy MM Wilson JW Ballas LM Carter K Darges JW Davis JE Hubbard FR Stamper ML 《Journal of medicinal chemistry》2002,45(12):2624-2643
A series of analogues of the protein kinase C (PKC) inhibitory natural product balanol which bear modified benzophenone subunits are described. The analogues were designed with the goal of uncovering structure-activity features that could be used in the development of PKC inhibitors with a reduced polar character compared to balanol itself. The results of these studies suggest that most of the benzophenone features found in the natural product are important for obtaining potent PKC inhibitory compounds. However, several modifications were found to lead to selective inhibitors of the related enzyme protein kinase A (PKA), and several specific modifications to the polar structural elements of the benzophenone were found to provide potent PKC inhibitors. In particular, it was found that replacement of the benzophenone carboxylate with bioisosteric equivalents could lead to potent analogues. Further, a tolerance for lipophilic substituents on the terminal benzophenone ring was uncovered. These results are discussed in light of recently available structural information for PKA. 相似文献
29.
We have used the new Technicon H.1 Hematology Analyzer to determine the indices of erythrocytes obtained from 18 nonthalassemic (alpha alpha/alpha alpha genotype) adult patients with Hb SC disease. Controls were 14 normal black adults and 29 white adults. The data showed that SC erythrocytes are significantly smaller than normal RBC (P less than .001) with a significantly higher MCHC value (P less than .001) than controls. These features of SC RBC could not be reproduced by an Ortho ELT-8 electronic counter. Hb SC erythrocytes have unique indices which are best demonstrated either by semimanual methods or by the H.1 system. 相似文献
30.